Anavex Life Sciences (NASDAQ:AVXL) has met its enrollment target for the ANAVEX2-73 (blarcamesine) Phase 2 study in Parkinson’s Disease Dementia (PDD).
Topline results are expected by mid-2020.
The study enrolling over 120 patients measures
efficacy, tolerability, and safety of two different oral
ANAVEX2-73 doses or placebo.
Primary and secondary endpoints will assess
cognition and Parkinsonian motor symptoms and sleep function during the
14-week study.
Shares are up 5% premarket.
https://seekingalpha.com/news/3534606-anavex-life-completes-enrollment-in-mid-stage-blarcamesine-study-shares-up-5-premarket
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.